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Abstract
Background: Overviews of reviews (overviews) compile information from multiple systematic reviews (SRs) to
provide a single synthesis of relevant evidence for decision-making. It is recommended that authors assess and
report the methodological quality of SRs in overviews—for example, using A MeaSurement Tool to Assess systematic
Reviews (AMSTAR). Currently, there is variation in whether and how overview authors assess and report SR quality,
and limited guidance is available. Our objectives were to: examine methodological considerations involved in using
AMSTAR to assess the quality of Cochrane and non-Cochrane SRs in overviews of healthcare interventions; identify
challenges (and develop potential decision rules) when using AMSTAR in overviews; and examine the potential impact
of considering methodological quality when making inclusion decisions in overviews.
Methods: We selected seven overviews of healthcare interventions and included all SRs meeting each overview’s
inclusion criteria. For each SR, two reviewers independently conducted AMSTAR assessments with consensus
and discussed challenges encountered. We also examined the correlation between AMSTAR assessments and SR
results/conclusions.
Results: Ninety-five SRs were included (30 Cochrane, 65 non-Cochrane). Mean AMSTAR assessments (9.6/11 vs.
5.5/11; p < 0.001) and inter-rater reliability (AC1 statistic: 0.84 vs. 0.69; “almost perfect” vs. “substantial” using the
Landis & Koch criteria) were higher for Cochrane compared to non-Cochrane SRs. Four challenges were identified
when applying AMSTAR in overviews: the scope of the SRs and overviews often differed; SRs examining similar
topics sometimes made different methodological decisions; reporting of non-Cochrane SRs was sometimes poor;
and some non-Cochrane SRs included other SRs as well as primary studies. Decision rules were developed to address
each challenge. We found no evidence that AMSTAR assessments were correlated with SR results/conclusions.
Conclusions: Results indicate that the AMSTAR tool can be used successfully in overviews that include Cochrane and
non-Cochrane SRs, though decision rules may be useful to circumvent common challenges. Findings support existing
recommendations that quality assessments of SRs in overviews be conducted independently, in duplicate, with a
process for consensus. Results also suggest that using methodological quality to guide inclusion decisions
(e.g., to exclude poorly conducted and reported SRs) may not introduce bias into the overview process.
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Background
Systematic reviews (SRs) aim to answer a specific clinical
question by identifying, selecting, appraising and synthe-
sizing all relevant primary studies using explicit and
well-defined methods [1]. The number of published SRs
is constantly increasing [2]. To help manage this infor-
mation overload, overviews of reviews (overviews) have
emerged as an increasingly popular knowledge synthesis
product. Overviews use explicit and systematic methods
to integrate information from multiple related SRs to
provide a comprehensive synthesis of all SR evidence re-
lated to a specific clinical question [3]. As a result, over-
views are broader in scope than any individual SR, and
often examine evidence from multiple SRs to assess the
efficacy or effectiveness of multiple interventions for
preventing or treating one specific clinical condition.
Overviews can include both SRs published in and out-
side of the Cochrane Database of Systematic Reviews
(CDSR; referred to as “Cochrane SRs” and “non-
Cochrane SRs”, respectively). An estimated 48-86% of
published overviews include both Cochrane and non-
Cochrane SRs, while the remaining overviews include
Cochrane SRs only [4–6].
There is consensus in the research community that re-
searchers conducting overviews of healthcare interven-
tions ought to assess and report the methodological
quality of the SRs included in their overview [7]. These
assessments should ideally be conducted by two inde-
pendent reviewers, with a process for consensus, and re-
ported transparently [3, 7]. However, researchers
conducting overviews have indicated that assessing
methodological quality of SRs may be difficult and time-
consuming [7]. Studies have indicated that only 37-64%
of published overviews assess and report the methodo-
logical quality of their included SRs, and among these
overviews, there is variation in the methods used [4–6].
This variation is not surprising, as to date there is limi-
ted guidance regarding the specific methods that should
be used to assess SR quality.
Quality assessments of SRs are important in overviews
for two main reasons. First, quality assessments should
be used by overview authors when making conclusions
in overviews (e.g., to help contextualize the evidence by
providing insight into whether and to what extent SR
methods may have affected the comprehensiveness and
results of overviews). However, it is not known whether
and how existing quality assessment criteria need to be
modified for use in overviews [7]. Assessing the quality
of SRs in the context of overviews may pose unique
challenges, and decision rules may be helpful to promote
consistent assessments both within and across overview
topics. Second, results of quality assessments may help
inform inclusion decisions [7]. This may be especially
relevant when including non-Cochrane SRs in overviews.
On average, non-Cochrane SRs have lower methodo-
logical rigor than Cochrane SRs, and the methods and
reporting of non-Cochrane SRs can vary widely [8–10].
Researchers conducting overviews have indicated that
including lower-quality SRs in overviews can increase
the complexity of the overview process because data
may be missing, poorly reported, or inconsistently re-
ported in the SRs, and it is unclear what to do in these
situations (e.g., should overview authors refer back to
the relevant primary studies, or attempt to use the
poorly conducted and/or reported SRs?) [7]. However,
existing methodological guidance on this topic is con-
flicting [7]. One potential solution proposed by re-
searchers [7] and employed by overview authors [11–18]
is to use the results of methodological quality assess-
ments to identify and exclude SRs with gross deficiencies
in conduct and/or reporting that would be difficult to
include and use in overviews. However, using results of
quality assessments to inform inclusion decisions may
introduce bias if the results and conclusions of these SRs
differ systematically from other well-conducted and re-
ported SRs.
A MeaSurement Tool to Assess systematic Reviews
(AMSTAR) is the most frequently mentioned tool for
assessing SR quality in overviews [7]. AMSTAR consists
of eleven questions designed to assess the appropriate-
ness of the methods used at different stages of the SR
process, and it has been shown to be reliable, valid, and
easy to use when assessing the quality of published SRs
[19–21]. The objectives of the present study were: 1) to
examine methodological considerations involved in using
the AMSTAR tool to assess the quality of Cochrane and
non-Cochrane SRs in overviews of healthcare interven-
tions, 2) to identify challenges involved when using
AMSTAR in overviews and to develop potential decision
rules to overcome these challenges, and 3) to examine the
potential impact of considering methodological quality
when making inclusion decisions in overviews. To achieve
the above objectives, we examined AMSTAR assessments,
inter-rater reliability of AMSTAR, the association between
AMSTAR assessments and inter-rater reliability, and the
association between AMSTAR assessments and results




This descriptive study used a convenience sample of
seven overviews of healthcare interventions that were
selected from overviews conducted by the Alberta
Research Centre for Health Evidence between 2010 to
2016. These overviews examined questions related to
the efficacy or effectiveness of multiple interventions for
preventing or treating clinical conditions related to
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pediatric health [22–28]. For each overview topic, all pub-
lished English-language Cochrane and non-Cochrane SRs
that met the overview’s inclusion criteria were identified
from the reference list of the published overview and in-
cluded in the study sample. All seven overviews included
Cochrane SRs, and four also included non-Cochrane SRs.
For the three overviews that did not include non-
Cochrane SRs [23–25], we conducted additional literature
searches to locate and include relevant non-Cochrane
SRs. The literature searches were conducted by an infor-
mation specialist using the inclusion criteria and search
dates from each overview. Screening and inclusion were
conducted independently by two reviewers, with discrep-
ancies resolved by consensus or third party adjudication.
For feasibility, we restricted the scope of one overview
topic by population (outpatients only) [24]. Search strate-
gies for all overview topics are available in published over-
views and upon request.
AMSTAR assessments
Two reviewers used the AMSTAR tool to independently
assess the methodological quality of each SR included in
the sample. Each of the eleven questions in the
AMSTAR tool was answered “yes”, “no”, “can’t answer”,
or “unable to assess”, and discrepancies between re-
viewers for individual AMSTAR questions were resolved
via consensus or third party adjudication. In accordance
with other empirical studies assessing measurement
properties of AMSTAR [20, 21, 29–32], all items scoring
“yes” received one point, and points were summed to a
maximum of eleven for each SR.
When conducting AMSTAR assessments, reviewers
also independently documented any challenges or issues
that arose when assessing AMSTAR in the context of
the overview of interest, including which question(s) of
the AMSTAR tool were impacted by each challenge and
potential reasons why each challenge posed difficulties.
Reviewers also independently developed decision rules
that could be used to address the challenges identified.
Challenges and decision rules were discussed between
reviewers until agreement was reached and were then
summarized narratively.
Result and conclusion statement assessments
The following data about the results and conclusions of
each included SR were extracted: the outcome data for
the first outcome listed in the corresponding overview
(see Table 1); and the authors’ conclusion regarding that
outcome, as stated in the abstract, discussion and/or
conclusion section of each SR. For SRs that did not con-
tain results data for the overview’s first-listed outcome,
data were extracted for the overview’s second or third-
listed outcome, if available. For SRs that included more
than one comparison, the outcome data and conclusion
statement for the comparison that was listed first in the
relevant overview were extracted (as a proxy for the
most clinically relevant comparison). Outcome data
from the SRs contained within the procedural sedation
overview were not extracted, because data for the com-
parator group were often not available.
Results and conclusions from each SR were classified
based on published criteria [33, 34]. Results were classified
as “favourable” (p < 0.10 in favour of the intervention, or
finding described as ‘significant’), “neutral” (p > 0.10, or
finding described as ‘not different between groups’), or
“unfavourable” (p < 0.10 in favour of the comparator, or
finding described as ‘favouring non-intervention compara-
tor’). Conclusions were classified as “positive-strong”
(authors stated that there was clear evidence of effective-
ness, and no further research was required), “positive-
weak” (authors stated that there seemed to be evidence of
effectiveness, but more research was required to confirm
the findings), “neutral” (authors stated that there was no
or insufficient evidence about whether the intervention
was effective or not, and more research was required to
reach a conclusion), “negative-weak” (authors stated that
there seemed to be evidence against use of the interven-
tion, but more research was required to confirm the
Table 1 Overview topics and their included systematic reviews




Number of included systematic reviews
Cochrane Non-Cochrane Total
Acute asthma Pollock, 2017 [22] Hospital admission 7 6 13
Acute otitis media Oleszczuk, 2012 [23] Pain early in therapy 6 10 16
Bronchiolitis Bialy, 2011 [24] Hospital admission 4 3 7
Croup Bjornson, 2010 [25] Clinical score 4 2 6
Eczema Foisy, 2011 [26] Incidence of eczema 6 19 25
Gastroenteritis Freedman, 2013 [27] Hospital admission 3 12 15
Procedural sedation Hartling, 2016 [28] Adverse effectsa 0 13 13
Total 30 65 95
aWe were unable to extract primary outcome data from the systematic reviews included within the procedural sedation overview because data for the
comparator group were often not available
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findings), or “negative-strong” (authors stated that there
was clear evidence against use of the intervention, and no
further research was required). One reviewer extracted
and classified results data, and a second reviewer verified
the classifications. Two reviewers independently extracted
and classified conclusion statements, and discrepancies
were resolved by consensus.
Data analysis
AMSTAR assessments were summarized using means
and standard deviations (SD), and independent samples
t-tests were used to compare Cochrane and non-
Cochrane SRs. Medians and ranges were also examined.
The number and percentage of positive responses per
AMSTAR question were calculated, and chi square tests
were used to compare Cochrane and non-Cochrane SRs.
For descriptive purposes, AMSTAR assessments were di-
vided into categories using established criteria (AMSTAR
assessments of 0-3, 4-7, and 8-11) [17, 35, 36].
Inter-rater reliability for AMSTAR was calculated
using the alternative chance-correlated coefficient (AC1)
statistic, with 95% confidence intervals (CIs) [37, 38].
The AC1 statistic was used in place of the kappa statistic
in order to overcome the limitation of the “kappa para-
dox”, which occurs when high agreement between re-
viewers results in low kappa scores [39, 40]. Interpretation
of the AC1 statistic is similar to the kappa statistic: AC1
ranges from -1.00 (perfect disagreement) to 1.00 (perfect
agreement), with a value of zero indicating reliability
equivalent to chance. Accordingly, inter-rater reliability
was classified using criteria established by Landis & Koch:
“less than chance” (<0.00), “slight” (0.00 − 0.20), “fair”
(0.21 − 0.40), “moderate” (0.41 − 0.60), “substantial”
(0.61 − 0.80), and “almost perfect” (0.81 − 0.99) [41, 42].
An additional level of classification, “perfect” (1.00),
was also added. In addition, percentage agreement, with
95% CIs, was also calculated (overall, and per AMSTAR
question), and chi square tests were used to compare
Cochrane and non-Cochrane SRs.
Pearson correlation coefficients were used to correlate
AMSTAR assessments and inter-rater reliability for
Cochrane and non-Cochrane SRs. The strength of the
resulting correlations was described using established
criteria as “negligible” (0.00 − 0.30), “low” (0.30 − 0.50),
“moderate” (0.50 − 0.70), “high” (0.70 − 0.90), or “very
high” (0.90 − 1.00) [43]. For non-Cochrane SRs, a post-
hoc regression analysis using a quadratic model was also
examined (with AMSTAR assessments as the independent
variable). The relationships were then depicted graphically.
The distributions of result and conclusion assessments
were summarized using the number and percentage of
SRs obtaining each classification. Due to the ordinal na-
ture of the data, Mann-Whitney U-tests were used to
examine differences in the breakdown of result and
conclusion assessments for Cochrane compared to non-
Cochrane SRs, and Spearman correlation coefficients
were used to correlate AMSTAR assessments with result
and conclusion assessments.
A narrative summary of challenges involved in using
AMSTAR in overviews was also provided, and potential
solutions were described. AgreeStat 2015.5 was used to
calculate AC1 statistics (Advanced Analytics LLC.,
Gaitherburg, MD, USA). SPSS version 23 was used to
analyze numerical data (SPSS Inc., Chicago, IL, USA).
Results
Study sample
The study sample included 95 SRs—30 Cochrane SRs
and 65 non-Cochrane SRs—across seven overview topics
(Table 1). A list of included SRs, along with their
AMSTAR assessments, can be found in Additional file 1.
The mean AMSTAR assessment (/11) for the 95 SRs
was 6.8 (SD: 2.9), with ratings ranging from 1 to 11. The
mean AMSTAR assessment was 9.6 (SD: 1.6) for
Cochrane SRs and 5.5 (SD: 2.4) for non-Cochrane SRs.
AMSTAR assessments were significantly higher for
Cochrane compared to non-Cochrane SRs by a mean of
4.1 points (95% CI: 3.2, 5.1; p < 0.001). This pattern of
results was consistent across all overview topics (with
the exception of the procedural sedation topic, which
had no Cochrane SRs), with mean AMSTAR assess-
ments ranging from 1.4 points to 5.5 points higher per
topic area for Cochrane compared to non-Cochrane SRs
(Additional file 2, first table). Eighty-seven percent of the
Cochrane SRs had AMSTAR assessments of eight or
more, compared to 22% of non-Cochrane SRs. On the
other hand, 22% of the non-Cochrane SRs had AMSTAR
assessments of three or less, compared to 0% of Cochrane
SRs (Fig. 1a). Although AMSTAR assessments were not
normally distributed, mean and median assessments were
very similar, and median AMSTAR assessments were
higher for Cochrane compared to non-Cochrane SRs both
overall and per topic area (Additional file 2, first table).
On average, Cochrane SRs received more positive re-
sponses for each of the eleven questions of the AMSTAR
tool than the non-Cochrane SRs. This difference was
statistically significant for eight questions (Q1-Q7, Q11;
p ≤ 0.045). For Cochrane SRs, all eleven AMSTAR ques-
tions received positive responses more than 50% of the
time (range: 53-100% positive responses per question),
compared to 5/11 questions for non-Cochrane SRs
(range: 14-88% positive responses per question) (Table 2,
first column).
Inter-rater reliability
The mean inter-rater reliability between reviewers for
the 95 included SRs, as classified using the Landis &
Koch levels of classification [41], was “substantial”
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(AC1: 0.74; 95% CI: 0.70, 0.79), with inter-rater reli-
ability per SR ranging from “slight” (AC1: 0.09) to
“perfect” (AC1: 1.00). The mean inter-rater reliability
was one level higher for Cochrane compared to non-
Cochrane SRs: “almost perfect” for Cochrane SRs
(AC1: 0.84; 95% CI: 0.77, 0.91) compared to “substantial”
for non-Cochrane SRs (AC1: 0.69; 95% CI: 0.64, 0.75)
(Fig. 1b). For the six overview topics that included both
Cochrane and non-Cochrane SRs, mean inter-rater reli-
ability ranged from 0.05-0.45 points higher per topic area
for Cochrane compared to non-Cochrane SRs, and was at
least one level higher for Cochrane SRs for two of the six
overview topics (Additional file 2, first table). The same
pattern of results was observed when examining per-
centage agreement; namely, agreement was higher for
Cochrane compared to non-Cochrane SRs both overall,
and per topic area (Additional file 2, first table).
Inter-rater reliability for the eleven individual ques-
tions of the AMSTAR tool ranged from “substantial”
(Q2, Q8, Q10, Q11) to “perfect” (Q5, Q6) for the
Cochrane SRs, and from “moderate” (Q8) to “almost
perfect” (Q6) for the non-Cochrane SRs. Inter-rater
reliability was at least one level higher for Cochrane
compared to non-Cochrane SRs for 8/11 questions (Q1,
Q3-Q9) (Table 2, second column). A similar pattern was
observed when examining percentage agreement between
reviewers: Cochrane compared to non-Cochrane SRs had
higher agreement for 9/11 questions (Q1, Q3-Q9, Q11),
and this difference was significant for 3/11 questions (Q3,
Q5, Q7) (Additional file 2, second table).
Challenges involved when using AMSTAR in overviews,
and potential decision rules
Four main challenges were identified when assessing
AMSTAR in the context of overviews. These four chal-
lenges primarily affected the AMSTAR questions con-
cerned with quality assessments and data extraction and
analysis (i.e., Q5-Q10). Each challenge is described
below, along with the decision rule (and rationale) that
was developed to help address each challenge (Table 3).
First, many non-Cochrane SRs provided limited detail
when reporting the characteristics and evaluating the
quality of their included primary studies. This often
made it difficult to determine whether certain AMSTAR
criteria were met, and it was unclear whether deficien-
cies in SRs were related to methodological quality or
reporting. Overview authors rely upon the information
reported in the included SRs when conducting their
overview; therefore, we recommend awarding points
only if the amount and quality of information reported
in the SR is sufficient for use at the overview level.
Second, some SRs that examined the same interven-
tions for the same disorder analyzed outcome data in
different ways and/or reached different conclusions. It
was difficult to determine whether SR methods were ap-
propriate when different SRs used different methodolo-
gies, and we were uncertain whether multiple similar
SRs should be compared against each other when con-
ducting AMSTAR assessments. In these instances, it
may not be possible to objectively determine which con-
clusions or methods of analysis are most appropriate or
valid; therefore, we recommend awarding points only if
SR authors provide appropriate justification for why they
chose a certain method of analysis and/or why they
reached a certain conclusion.
Third, many SRs were broader in scope than the clinical
question posed in the overview, meaning that not all
primary studies included in the SRs were subsequently in-
cluded in the overview. Reviewers were unsure whether to
Fig. 1 AMSTAR assessments (a), and inter-rater reliability (b), for
Cochrane and non-Cochrane systematic reviews. * p < 0.001 in favour
of Cochrane systematic reviews (independent samples t-test); † Mean
inter-rater reliability was one level higher for Cochrane compared to
non-Cochrane SRs (“almost perfect” vs. “substantial”)
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assess the quality of the SRs in their entirety or whether to
assess the quality of only those components of the SRs
that were relevant to the overview topic. However,
attempting to isolate only the components of interest in
SRs was unnecessarily difficult and time-consuming, and
we agreed that it was important to capture information
about the conduct of the SRs as a whole. Therefore, we
recommend that overview authors assess the quality of
the overall SRs, without trying to “piece apart” only those
components that are relevant to the overview topic.
Lastly, difficulties were encountered when assessing
the quality of non-Cochrane SRs that included both pri-
mary studies and other SRs. It was unclear whether and
how to assess the quality of the SRs that were embedded
within the original SRs, and we were uncertain whether
the AMSTAR assessments of the original SRs should be
affected by the quality of the embedded SRs. When con-
ducting AMSTAR assessments, we found that it was
often not possible, nor desirable, to integrate the quality
of the embedded SRs into the AMSTAR assessments of
the original SRs. Therefore, when SRs include both pri-
mary studies and other embedded SRs, we recommend
that overview authors treat each embedded SR as an in-
dependent publication by retrieving and assessing the
full text of that SR for inclusion into the overview. The
AMSTAR assessments for the overview can then
proceed as usual by assessing the quality of each in-
cluded SR separately.
Association between AMSTAR assessments and inter-rater
reliability
For Cochrane SRs, there was a significant positive linear
correlation of “moderate” strength between AMSTAR
assessments and inter-rater reliability (AC1), r(29) = 0.62,
p < 0.001. Thus, inter-rater reliability increased as quality
of Cochrane SRs increased. There was no evidence of a lin-
ear correlation between AMSTAR assessments and inter-
rater reliability for non-Cochrane SRs (p = 0.38). However,
visual examination of the scatterplot (Fig. 2) suggested a
quadratic (curvilinear) relationship, with higher inter-rater
reliability for non-Cochrane SRs that received both lower
and higher assessments and lower inter-rater reliability for
non-Cochrane SRs that received moderate assessments.
Therefore, a quadratic model was examined. Though not
statistically significant (p = 0.09), results suggest that inter-
rater reliability may be lower for non-Cochrane SRs with
moderate AMSTAR assessments and higher for non-
Cochrane SRs with lower and higher ratings (Fig. 2).
Association between AMSTAR assessments and results
and conclusions of systematic reviews
There was no significant difference in the distribution of
the results assessments for Cochrane compared to non-
Cochrane SRs (p = 0.14) (Table 4). There was also no
significant evidence of correlation between AMSTAR as-
sessments and the direction of effect for the main result
of each SR when looking at all SRs combined (p = 0.53),
Cochrane SRs only (p = 0.30), or non-Cochrane SRs only
(p = 0.72).
The data indicated a significant difference in the distri-
bution of the conclusion assessments for Cochrane com-
pared to non-Cochrane SRs (p = 0.035). Specifically,
Cochrane SRs reported significantly more “negative”
conclusions, whereas non-Cochrane SRs reported sig-
nificantly more “positive” conclusions (Table 4). Despite
these group differences, AMSTAR assessments were not
correlated with the direction and strength of effect for
the main conclusion of each SR when looking at all SRs
combined (p = 0.17), Cochrane SRs only (p = 0.68), or
non-Cochrane SRs only (p = 0.80).
Discussion
The current study used a convenience sample of 95 SRs
included across seven overview topics to provide empiri-
cal evidence on issues surrounding quality assessments
of SRs in overviews. This study found that AMSTAR as-
sessments and inter-rater reliability were higher for
Cochrane compared to non-Cochrane SRs; these results
were consistent within each overview topic and for many
of the individual questions of the AMSTAR tool. Minor
challenges were encountered when assessing quality of
SRs in the context of overviews, but decision rules were
developed and recommendations for overview authors
were provided. Results also suggested that inter-rater re-
liability of Cochrane and non-Cochrane SRs may be
lower for SRs with moderate AMSTAR assessments and
higher for SRs that were assessed as strong; inter-rater
reliability may also be higher for non-Cochrane SRs
assessed as weak. Consistent with a previous study [33],
we found that the conclusions, but not the results, of
Fig. 2 Pearson correlation between AMSTAR assessments and
inter-rater reliability, for Cochrane and non-Cochrane systematic reviews.
Linear relationship (Cochrane): p < 0.001; Quadratic relationship
(non-Cochrane): p = 0.09
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Cochrane and non-Cochrane SRs differed systematically;
however, the current study found no evidence that
AMSTAR assessments were correlated with results or
conclusions of SRs.
Taken together, the results of the current study suggest
that AMSTAR is a useful tool for assessing the quality of
Cochrane and non-Cochrane SRs in overviews. Authors
should be aware of some minor challenges they may face
when applying AMSTAR in overviews. Specifically, there
may be deficiencies in the reporting of some SRs; SRs
examining similar topics may sometimes make different
methodological decisions; the scope of some SRs may
differ from, or be broader than, the scope of the over-
view; and some non-Cochrane SRs may include other
SRs as well as primary studies. We recommend that
overview authors use a priori decision rules, such as
those presented in Table 4, to circumvent these chal-
lenges and help ensure consistent judgments across re-
viewers. In addition, Cochrane currently recommends
that quality assessments of SRs in overviews be con-
ducted independently, in duplicate, with a process for
consensus [3], and the results of this study provide
empirical evidence to support this recommendation.
Specifically, Cochrane SRs showed some variation in
AMSTAR assessments and inter-rater reliability, and non-
Cochrane SRs had lower AMSTAR assessments and inter-
rater reliability combined with higher variation for both of
these variables. To promote transparency, we also recom-
mend that overview authors provide breakdowns of indi-
vidual AMSTAR questions for all included SRs.
The current study found that the AMSTAR tool can
be used with high inter-rater reliability to successfully
identify SRs with lower quality assessments that may be
difficult to use in overviews due to gross deficiencies in
conduct and reporting. This study also found that
AMSTAR assessments were not correlated with results
or conclusions of SRs. The lack of correlation may be
due to a common criticism of AMSTAR— namely, that
AMSTAR may actually assess quality of reporting as well
as (or instead of ) methodological quality [44–46]. Qual-
ity of reporting may not necessarily be associated with
SR results and conclusions. However, reporting is closely
tied to usability of SRs in overviews, since overview au-
thors cannot effectively use SRs in overviews if the data
are missing, inadequately reported, or reported incon-
sistently [7]. The results of this study suggest that over-
view authors may consider using AMSTAR assessments
to guide inclusion decisions (e.g., to identify and exclude
poorly conducted and/or reported SRs that may be diffi-
cult to use in overviews). Using the AMSTAR tool to in-
form inclusion decisions may not introduce bias into the
overview process since the results and conclusions of
SRs assessed as weak and strong did not differ systematic-
ally. However, overview authors should use their judgment
when deciding whether or not to use results of AMSTAR
assessments to guide inclusion decisions. Factors to con-
sider include the quality of the overall body of SR evidence
and the purpose of the overview. For example, overview au-
thors may not need to include poorly conducted and re-
ported SRs when there are adequately conducted SRs that
address all main interventions and outcomes of interest. In
contrast, they may choose to retain poorly conducted and
reported SRs when the overall body of SR evidence is gen-
erally poor or when the purpose of the overview is to de-
scribe the complete body of SR evidence on a topic.
Though overall AMSTAR assessments may obscure effects
of individual questions [47], SRs that score poorly across
most AMSTAR domains likely have multiple serious limita-
tions that subsequently make them difficult to include and
use in overviews. To promote transparency, overview










reviews (n = 43a)
Results
Unfavourable 4 (14.3%) 0 (0.0%) 0.14
Neutral 14 (50.0%) 23 (53.5%)
Favourable 10 (35.7%) 20 (46.5%)
Conclusions
Negative-Strong 6 (21.4%) 1 (2.3%) 0.035b
Negative-Weak 6 (21.4%) 7 (16.3%)
Neutral 3 (10.7%) 7 (16.3%)
Positive-Weak 7 (25.0%) 13 (30.2%)
Positive-Strong 6 (21.4%) 15 (34.9%)
aTwenty-four systematic reviews (2 Cochrane, 22 non-Cochrane) were excluded from this analysis because they did not contain relevant outcome data; bConclusions of
Cochrane systematic reviews were more likely to be “negative” and conclusions of non-Cochrane systematic reviews were more likely to be “positive”
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authors should establish a priori decision rules indicating
whether and how quality assessments will be used to in-
form inclusion decisions; authors should also clearly indi-
cate in their overview which SRs (if any) were excluded
based on results of quality assessments or specific meth-
odological deficiencies.
This study identified areas where authors can enhance
the conduct and/or reporting of their Cochrane and non-
Cochrane SRs. Previous research shows that Cochrane
SRs generally have higher methodological rigour than
non-Cochrane SRs [8–10], and the results of the current
study extend this finding to SRs included in a sample of
overviews. Non-Cochrane SRs showed room for improve-
ment for all but two AMSTAR domains (Q6: study char-
acteristics; Q9: methods to combine studies). However,
not all Cochrane SRs received high assessments (13% were
rated between 4-7 on AMSTAR), and two AMSTAR do-
mains (Q10: publication bias; Q11: conflicts of interest)
showed considerable room for improvement. This study
also found that inter-rater reliability varied in conjunc-
tion with both AMSTAR assessments and type of SR
(Cochrane, non-Cochrane). Inter-rater reliability was
lower for SRs that obtained moderate AMSTAR assess-
ments (as opposed to very weak or strong assessments);
it was also lower for non-Cochrane SRs both overall
and for many of the individual AMSTAR domains (e.g.,
Q3: search strategy; Q7: scientific quality; Q8: formulating
conclusions). This may be because discrete “yes/no” judg-
ments become more difficult when quality and/or report-
ing is mediocre, or when only some criteria for multi-part
questions are addressed in the SR. The variable reporting
of non-Cochrane SRs, combined with limits on manuscript
length, may also contribute to difficulties conducting
AMSTAR assessments. Adhering to accepted standards of
conduct and reporting, such as the methods guidance
contained within The Cochrane Handbook for Systematic
Reviews of Interventions [48] and the Preferred Reporting
Items for Systematic reviews and Meta-Analysis (PRISMA)
reporting guidelines [49], can help ensure adequate quality
and reporting of SRs (and may also increase the inter-
rater reliability of quality assessments for SRs). This
could, in turn, make SRs easier to assess, include, and
use in overviews.
The current study used a convenience sample of over-
view topics that met specific inclusion criteria and shared
certain characteristics (e.g., all overviews were conducted
by our research group and examined interventions for dis-
orders related to pediatric health). Though the researchers
conducting this study were authors of all included over-
views, they were only authors of three of the 95 included
SRs, and duplicate independent quality assessments were
conducted to mitigate the potential for reviewer bias. It
is possible that the overview topics selected for this
study may have influenced the results to some extent;
however, to increase the generalizability of the know-
ledge gained from this study, overviews were selected
that examined a range of populations (e.g., infants, chil-
dren, adolescents), interventions (e.g., pharmacological,
non-pharmacological), comparators (e.g., placebo, ac-
tive comparators), research questions (e.g., prevention,
treatment), and topic areas (e.g., acute respiratory infec-
tions, gastrointestinal diseases, skin disorders). In addition,
we found that the AMSTAR assessments obtained for the
SRs in our sample of seven overviews fell within the range
of scores observed in a broader sample of overviews (all
relevant overviews identified by [4] and [5] and contained
within issue 12, 2016 of the CDSR). Our inter-rater reli-
ability assessments were also similar to published data
on agreement for AMSTAR [50]. Thus, the results of
the current study, and subsequent recommendations
for quality assessment of SRs in overviews, may ge-
neralize to a range of overviews examining healthcare
interventions. However, results and recommendations
should not be generalized to overviews that address
broader or different clinical questions (e.g., diagnostic
test accuracy, prognostic, or qualitative overviews).
It should be noted that there is debate surrounding
whether or not overall AMSTAR scores should be calcu-
lated. The developers of AMSTAR addressed this con-
cern by ensuring (through statistical analysis) that the
component questions do not overlap and by validating
the overall score against an external standard. Thus, they
concluded that the overall score is meaningful [21].
However, overall quality scores assume that all questions
are equal (which can be difficult to justify) [50, 51], sum-
ming individual items may artificially increase the preci-
sion of the assessment, and studies have shown that
incorporating overall quality of primary studies into
meta-analyses can alter effect estimates in SRs [52, 53].
Despite the uncertainty regarding use of summary
scores, there is a precedent for calculating and reporting
overall AMSTAR assessments both in empirical studies
assessing measurement properties of AMSTAR [20, 21,
29–32, 54–56] and in overviews of healthcare interven-
tions [16, 18, 35, 36, 57–71], and incorporating overall
quality of SRs into results of overviews has not been
found to alter overview results [72]. Other potential lim-
itations of AMSTAR may include difficulty meaningfully
differentiating between several of the response options
(“no”, “not applicable”, and “can’t answer”) and difficulty
answering multi-part questions when only some criteria
are met [44, 45]. There are also no questions in the
AMSTAR tool examining whether appropriate methods
were used in SRs to assess the quality of a body of evi-
dence or to conduct subgroup and/or sensitivity analyses
[44, 45], and in the context of overviews AMSTAR can-
not capture potentially important differences in compre-
hensiveness and recency of searches across SRs. As
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previously mentioned, the AMSTAR tool may also assess
aspects related to quality of reporting as opposed to
methodological quality [44–46]. Despite these potential
limitations, the results of this study demonstrate that
reviewers can conduct AMSTAR assessments with ad-
equate inter-rater reliability, using decision rules to help
overcome some of the above-listed challenges.
In addition to AMSTAR, other quality assessment tools
exist. AMSTAR 2 is currently being developed in response
to feedback from users of the original AMSTAR tool [73],
and the Risk Of Bias In Systematic reviews (ROBIS) tool
was recently published to assess issues related to the risk of
bias (as opposed to the methodological quality) of SRs [74].
Methodological research examining the reliability, validity,
and feasibility of AMSTAR 2 and ROBIS in overviews
would be valuable. In addition, research comparing
AMSTAR, AMSTAR 2 and ROBIS on important out-
comes (e.g., quality assessments, inter-rater reliability, and
time to complete assessments) and across important com-
parisons (e.g., Cochrane vs. non-Cochrane SRs, SRs with
meta-analyses vs. narrative summaries, and publication year
of SRs) may provide insight into the trade-offs involved in
selecting one tool over another for use in overviews.
Conclusions
There is currently limited guidance available for re-
searchers conducting overviews of healthcare interven-
tions. This gap in guidance is most pronounced when
examining methods for conducting the latter stages of
the overview process (e.g., quality assessments and data
extraction and analysis). The current study plays a role
in addressing this gap in guidance. It contributes empir-
ical evidence and recommendations regarding the use of
the AMSTAR tool to assess the methodological quality
of SRs in overviews. Based on the results of this study,
we show that AMSTAR can be used successfully to as-
sess the methodological quality of both Cochrane and
non-Cochrane SRs included in overviews of healthcare
interventions. When using AMSTAR in overviews, indi-
vidual assessments should be reported for each of the
eleven questions of the AMSTAR tool. Results of quality
assessments of SRs can then be used alongside quality
assessments of primary studies and outcome data to
help contextualize the results and conclusions of
overviews.
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